Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced the close of a $21.5 million Series B financing.

Orlando Health Ventures led the financing with significant participation from new investors Intuitive Surgical, Inc., Windham Venture Partners, and Rex Health Ventures, as well as additional investment from existing investors Spring Mountain Capital and Colle Capital. The Series B funding brings the total raised by Vergent to date to $34 million.